REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables)

3 Months Ended

Mar. 31, 2018

Revenue Recognition [Abstract]

Disaggregation of Revenue

The following table depicts the disaggregation of revenue according to contract type as of:

	Three Months Ended
(in thousands)	March 31, 2018		March 31, 2017
Sales of generic pharmaceutical products	$	23,227	$	26,572
Sales of branded pharmaceutical products		16,595		8,039
Sales of contract manufactured products		945		1,793
Royalties on sales of pharmaceutical products		5,382		-
Other(1)		334		224
Total net revenues	$	46,483	$	36,628

⁽¹⁾ Primarily includes laboratory services and royalties on sales of contract manufactured products

Schedule of Valuation and Qualifying Accounts Disclosure

The following table summarizes activity in the consolidated balance sheets for accruals and allowances for the three months ended March 31, 2018 and 2017, respectively:

	Accruals for Chargebacks, Rebates, Returns, and Other Allowances
							Administrative		Prompt
			Government				Fees and Other		Payment
(in thousands)	Chargebacks		Rebates		Returns		Rebates		Discounts
Balance at December 31, 2016	$	26,785	$	5,891	$	5,756	$	3,550	$	1,554
Accruals/Adjustments		38,191		1,821		1,855		5,030		1,662
Credits Taken Against Reserve		(40,442)		(3,057)		(1,835)		(4,755)		(1,737)
Balance at March 31, 2017	$	24,534	$	4,655	$	5,776	$	3,825	$	1,479
Balance at December 31, 2017	$	28,230	$	7,930	$	8,274	$	5,226	$	1,834
Accruals/Adjustments		38,217		1,795		3,644		7,584		1,890
Credits Taken Against Reserve		(42,696)		(3,254)		(2,898)		(6,792)		(2,142)
Balance at March 31, 2018	$	23,751	$	6,471	$	9,020	$	6,018	$	1,582